#VKTX Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
@stocktitan.net
@stocktitan.net#VKTX Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
@tickerade.bsky.social📉 Viking Therapeutics #VKTX is facing after-hours pressure despite a recently completed equity raise with ~5% dilution and promising VK2735 obesity-treatment data, as dark-pool activity signals investor caution.
#clinicaltrials #obesity
@newsen.bsky.socialViking Therapeutics Successfully Upsizes Its $500 Million Offering of Common Stock and Convertible Senior Notes #United_States #San_Diego #Clinical_Trials #Viking_Therapeutics #VKTX
@stocktitan.net#VKTX Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
@yuuiko7.bsky.social$VKTX raising $400M through stock and convertible note offerings
- Dual offering: common shares + convertible notes
- Proceeds aimed at expanding pipeline and operations
- Dilution risk on the table for current holders
@stocktitan.net#VKTX Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
@wallstgamenotes.bsky.social$VKTX surges 35% on weight loss drug trial. Wall Street loves it again. #VKTX #Stock #Investing #Finance #BioTechInvesting
@tradersaan.bsky.social
@stockmaster70.bsky.social
@robot2trade.bsky.social
